لخّصلي

Patients' clinical data were collected.Indexes recorded and measured by CGMS included (1) Mean Blood Glucose (MBG); (2) Standard Deviation of Blood Glucose (SDBG); (3) Mean Amplitude of Glycemic Excursion (MAGE): 24-hour amplitude variations of the subjects' glycemic excursion were measured and statistically analyzed, with the mean amplitude value of all glycemic variations calculated; (4) Absolute Means of Daily Differ- ence (MODD): corresponding values of the subjects' blood glucose in the two successive 24 hours, which were mea- sured and recorded at the same time stage of the day, were compared, with differences between the two being calcu- lated and a mean value of the difference obtained; and (5) 0 93% to 6 68+-0 73% after the treatment (P<0 001).Fasting blood glucose (FBG), HbA1c, and biochemical indexes were measured and recorded by a specially assigned physician.For CGMS measurement, a 72-hour CGMS (Medtronic MiniMed, USA) was applied to all subjects before and at week 26 of the treatment.The starting dosage of glimepiride was 1 mg, and the dosage could be adjusted on week 4 or 8, based on the patient's glu- cose level.The subjects were required to record their time of eating and monitor and record their finger peripheral blood glucose at least 4 times/day and hypoglycemic episodes (blood glucose < 3 9 mmol/L).For those who were taking antidiabetic drugs, they would spend two weeks after passing the screening procedure as the washing-out period before receiving the treatments.They were instructed to take food when their blood glucose was lower than 3.9 mmol/L.

Patients’ clinical data were collected. Fasting blood glucose (FBG), HbA1c, and biochemical indexes were measured and recorded by a specially assigned physician. The starting dosage of glimepiride was 1 mg, and the dosage could be adjusted on week 4 or 8, based on the patient’s glu- cose level. For those who were taking antidiabetic drugs, they would spend two weeks after passing the screening procedure as the washing-out period before receiving the treatments.
For CGMS measurement, a 72-hour CGMS (Medtronic MiniMed, USA) was applied to all subjects before and at week 26 of the treatment. The subjects were required to record their time of eating and monitor and record their finger peripheral blood glucose at least 4 times/day and hypoglycemic episodes (blood glucose < 3 9 mmol/L). They were instructed to take food when their blood glucose was lower than 3.9 mmol/L.
Indexes recorded and measured by CGMS included (1) Mean Blood Glucose (MBG); (2) Standard Deviation of Blood Glucose (SDBG); (3) Mean Amplitude of Glycemic Excursion (MAGE): 24-hour amplitude variations of the subjects’ glycemic excursion were measured and statistically analyzed, with the mean amplitude value of all glycemic variations calculated; (4) Absolute Means of Daily Differ- ence (MODD): corresponding values of the subjects’ blood glucose in the two successive 24 hours, which were mea- sured and recorded at the same time stage of the day, were compared, with differences between the two being calcu- lated and a mean value of the difference obtained; and (5) 0 93% to 6 68±0 73% after the treatment (P